Kusajili – Clinical trials directory

Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer Trial of sorafenib versus placebo in the treatment of locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine

• Country Austria, Belgium, Bulgaria, China, Denmark, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Saudi Arabia, Slovakia, Spain, Sweden, United Kingdom, United States,
• organs None
• Specialty None

International Pediatric Peritoneal Biopsy Study in Children on PD and Healthy Controls

• Country Austria, Belgium, Czech Republic, France, Germany, Hungary, Italy, Lebanon, Lithuania, Malaysia, Spain, Sweden, Switzerland, Turkey, United States,
• organs None
• Specialty None

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

• Country Austria, Belgium, Denmark, France, Germany, Italy, Netherlands, Serbia, Sweden, Switzerland, United States,
• organs None
• Specialty None

Radiation Therapy or Temozolomide in Treating Patients With Gliomas

• Country Australia, Outside, Austria, Belgium, Canada, Egypt, France, Germany, Hungary, Israel, Luxembourg, Netherlands, New Zealand, Portugal, Singapore, Spain, Sweden, Switzerland, United Kingdom,
• organs None
• Specialty None

Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP) The objectives of this program are: to further characterize the natural progression of MPS VI disease; to generate and disseminate information on the care and management of MPS VI patients to clinical and medical professionals; to provide a resource to physicians and patients by providing information for optimizing patient care based on aggregate data; to characterize the clinical response to long-term Naglazyme® (galsulfase) treatment; to further characterize the long-term safety of Naglazyme® treatment.

• Country Australia, Austria, Belgium, France, Germany, Ireland, Italy, Lithuania, Netherlands, Portugal, Sweden, United Kingdom, United States,
• organs None
• Specialty None